Please login to the form below

Not currently logged in
Email:
Password:

ArQule

This page shows the latest ArQule news and features for those working in and with pharma, biotech and healthcare.

Merck gets first approval for MET inhibitor tepotinib in Japan

Merck gets first approval for MET inhibitor tepotinib in Japan

ArQule and Kyowa Hakko abandoned their MET inhibitor tivantinib in 2017 after a string of trial failures, while GlaxoSmithKline/Exelixis’ also seem to have dropped their MET/VEGF inhibitor foretinib and

Latest news

More from news
Approximately 2 fully matching, plus 5 partially matching documents found.

Latest appointments

  • X4 appoints John Celebi as COO X4 appoints John Celebi as COO

    Most recently, he served as chief business officer of Igenica Biotherapeutics, and has previously held senior positions at Agilent Technologies, ArQule, Biogen and Cyclis Pharmaceuticals.

  • Dr Jessie English joins Merck Dr Jessie English joins Merck

    During her two decades of work in oncology and immune-oncology research, she has also served as vice president of kinase biology at ArQule, oncology site lead for external discoveries at

More from appointments
Approximately 0 fully matching, plus 2 partially matching documents found.

Subscribe to our email news alerts

Featured jobs

PMHub

Add my company
Collected Group

Collected Group is a forward thinking healthcare communication company that supports biopharma and diagnostic companies to engage in more lasting...

Latest intelligence

Our Top 5 Pharma Picks From Cannes Lions
Here are five of Art's top five pharma and healthcare picks from Cannes Lions 2022....
The Evolving Role of the Sales Rep
The COVID-19 pandemic sparked an evolution in physician engagement. Jill Padgett, EdD, Head of Training, explores what this means for the sales force and shares her advice for succeeding in...
Measure your omnichannel maturity with our new tool
Try our Omnichannel Maturity Tool to gain tangible advice and an instant analysis of your omnichannel readiness....